Psyence Biomedical Ltd. Common Shares (PBM) - Total Assets
Based on the latest financial reports, Psyence Biomedical Ltd. Common Shares (PBM) holds total assets worth $12.81 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Psyence Biomedical Ltd. Common Shares - Total Assets Trend (2021–2025)
This chart illustrates how Psyence Biomedical Ltd. Common Shares's total assets have evolved over time, based on quarterly financial data. Also see PBM market cap overview for the company's overall valuation and market capitalisation.
Psyence Biomedical Ltd. Common Shares - Asset Composition Analysis
Current Asset Composition (March 2025)
Psyence Biomedical Ltd. Common Shares's total assets of $12.81 Million consist of 89.7% current assets and 10.3% non-current assets. Review PBM liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.9% |
| Accounts Receivable | $137.35K | 1.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Psyence Biomedical Ltd. Common Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Psyence Biomedical Ltd. Common Shares stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Psyence Biomedical Ltd. Common Shares's current assets represent 89.7% of total assets in 2025, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 83.9% of total assets in 2025, down from 97.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 1.9% of total assets.
Psyence Biomedical Ltd. Common Shares Competitors by Total Assets
Key competitors of Psyence Biomedical Ltd. Common Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Psyence Biomedical Ltd. Common Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.09 | 0.64 | 0.05 |
| Quick Ratio | 8.09 | 0.64 | 0.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.69 Million | $-1.27 Million | $-227.28K |
Psyence Biomedical Ltd. Common Shares - Advanced Valuation Insights
This section examines the relationship between Psyence Biomedical Ltd. Common Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.26 |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | 546.2% |
| Total Assets | $7.32 Million |
| Market Capitalization | $3.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values Psyence Biomedical Ltd. Common Shares's assets below their book value (0.43x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Psyence Biomedical Ltd. Common Shares's assets grew by 546.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Psyence Biomedical Ltd. Common Shares (2021–2025)
The table below shows the annual total assets of Psyence Biomedical Ltd. Common Shares from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $7.32 Million | +546.23% |
| 2024-03-31 | $1.13 Million | -99.56% |
| 2023-03-31 | $258.93 Million | +1.06% |
| 2022-03-31 | $256.22 Million | +5127.05% |
| 2021-03-31 | $4.90 Million | -- |
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more